Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.58 - $1.03 $27,168 - $48,247
-46,842 Reduced 92.13%
4,000 $2,000
Q1 2024

May 10, 2024

BUY
$0.6 - $0.9 $5,673 - $8,510
9,456 Added 22.85%
50,842 $45,000
Q4 2023

Feb 09, 2024

BUY
$0.65 - $0.86 $4,847 - $6,413
7,458 Added 21.98%
41,386 $31,000
Q3 2023

Nov 13, 2023

SELL
$0.65 - $1.25 $11,406 - $21,935
-17,548 Reduced 34.09%
33,928 $23,000
Q2 2023

Aug 15, 2023

BUY
$1.08 - $1.65 $50,269 - $76,800
46,546 Added 944.14%
51,476 $61,000
Q1 2023

May 12, 2023

BUY
$0.78 - $1.42 $10 - $19
14 Added 0.28%
4,930 $5,000
Q4 2022

Feb 13, 2023

BUY
$0.79 - $1.28 $18 - $29
23 Added 0.47%
4,916 $3,000
Q3 2022

Nov 14, 2022

SELL
$0.14 - $1.33 $0 - $9
-7 Reduced 0.14%
4,893 $6,000
Q2 2022

Aug 12, 2022

SELL
$0.88 - $1.87 $21,843 - $46,417
-24,822 Reduced 83.51%
4,900 $5,000
Q1 2022

May 16, 2022

SELL
$1.38 - $1.89 $51,661 - $70,754
-37,436 Reduced 55.74%
29,722 $53,000
Q4 2021

Feb 14, 2022

SELL
$1.51 - $2.2 $877,977 - $1.28 Million
-581,442 Reduced 89.65%
67,158 $103,000
Q3 2021

Nov 15, 2021

BUY
$1.74 - $2.6 $1.12 Million - $1.67 Million
644,062 Added 14192.64%
648,600 $1.32 Million
Q2 2021

Aug 16, 2021

BUY
$1.51 - $4.23 $2,746 - $7,694
1,819 Added 66.9%
4,538 $15,000
Q1 2021

May 13, 2021

BUY
$1.04 - $2.34 $473 - $1,064
455 Added 20.1%
2,719 $5,000
Q4 2020

Feb 09, 2021

BUY
$0.9 - $1.2 $14 - $19
16 Added 0.71%
2,264 $2,000
Q3 2020

Nov 05, 2020

BUY
$0.83 - $1.51 $109 - $199
132 Added 6.24%
2,248 $2,000
Q2 2020

Aug 13, 2020

SELL
$0.65 - $1.45 $10,705 - $23,881
-16,470 Reduced 88.62%
2,116 $2,000
Q1 2020

May 14, 2020

BUY
$0.46 - $1.3 $8,549 - $24,161
18,586 New
18,586 $11,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $378M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.